Overview

• Indivior, known for its opioid addiction and schizophrenia treatments, intends to shift its primary listing to the US, potentially as early as this summer.
• The move is propelled by the significant US market opportunity for its products, with nearly half of its shares already owned by US investors.
• Shares in Indivior surged by as much as 22% following the announcement, marking the highest increase since late November.
• The relocation is part of a broader trend of companies leaving the London Stock Exchange, raising concerns about London's status as a leading financial hub.
• Indivior's decision comes amid efforts by UK ministers to reform listing regulations to make London a more attractive market for companies.